Biodexa Pharmaceuticals PLC Announces US$3.32 Million Registered Direct Offering
24 mai 2023 08h40 HE
|
Biodexa Pharmaceuticals PLC
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH...
Ivy Brain Tumor Center Builds On Innovative Clinical Trial Program by Appointing New Chief Medical Officer
23 mai 2023 13h43 HE
|
Ivy Brain Tumor Center
Phoenix, Arizona, May 23, 2023 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center and Barrow Neurological Institute are pleased to announce the addition of Yoshie Umemura, MD, as the new Chief Medical...
Posting of Annual Report & Notice of AGM
22 mai 2023 16h15 HE
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Posting of Annual Report & Notice of AGM Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company...
Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals
18 mai 2023 08h30 HE
|
Biodexa Pharmaceuticals PLC
18 May 2023 Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the...
Preliminary Results for the Year Ended 31 December 2022
28 avr. 2023 16h30 HE
|
Biodexa Pharmaceuticals PLC
28 April 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2022 Biodexa Pharmaceuticals...
Brain Cancer Market Size to Propel With the Active Participation of Key Leading Such as Bayer, MedImmune, Daiichi Sankyo, Genentech, Merck, and Others, Assesses DelveInsight
22 mars 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, March 22, 2023 (GLOBE NEWSWIRE) -- Brain Cancer Market Size to Propel With the Active Participation of Key Leading Such as Bayer, MedImmune, Daiichi Sankyo, Genentech, Merck, and...
The Voice Finalist Morgan Myles Joins the Glioblastoma Foundation® as a Celebrity Ambassador to Raise Awareness and Funding for Glioblastoma
22 févr. 2023 09h08 HE
|
Glioblastoma Foundation
DURHAM, N.C., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Morgan Myles was a top three finalist on the latest season of NBC's The Voice, and now she is hopeful to use her voice in a different way — to share...
The Voice Finalist Morgan Myles Joins the Glioblastoma Foundation® as a Celebrity Ambassador to Raise Awareness and Funding for Glioblastoma
22 févr. 2023 09h08 HE
|
Glioblastoma Foundation
DURHAM, N.C., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Morgan Myles was a top three finalist on the latest season of NBC's The Voice, and now she is hopeful to use her voice in a different way — to share...
FLAG Therapeutics Receives Rare Pediatric Disease (RPD) Designation for FLAG-003 for the Treatment of Children with Diffuse Intrinsic Pontine Glioma (DIPG)
31 janv. 2023 13h00 HE
|
Flag Therapeutics, Inc.
RALEIGH, N.C., Jan. 31, 2023 (GLOBE NEWSWIRE) -- FLAG Therapeutics, Inc., announced today that FLAG-003, an investigational small molecule therapy for the treatment of Diffuse Intrinsic Pontine...
TVAX Biomedical Announces Receipt of $2 Million FDA Orphan Products Grant for Glioblastoma Study
18 oct. 2022 10h07 HE
|
TVAX Biomedical
OLATHE, Kan., Oct. 18, 2022 (GLOBE NEWSWIRE) -- TVAX Biomedical (TVAX) is a cancer immunotherapy company that is moving into its pivotal glioblastoma study for FDA regulatory approval. In September...